OFF-LABEL GLOFITAMAB INDUCES RAPID REVERSAL OF BONE MARROW FAILURE IN MANTLE CELL LYMPHOMA REFRACTORY TO BOTH COVALENT AND NON-COVALENT BTK INHIBITORS (SIE 2026) - Oct 6, 2026 - Abstract #SP094; "The patient underwent multiple lines of therapy: R-CHOP (CR), RB (PR), R-BAC (CR, ASCT declined), Ibrutinib (72 cycle, subsequent pro- gression) and pirtobrutinib (refractory disease). The rapid reversal of bone marrow failure highlights a po- tent anti-lymphoma effect in a setting with otherwise dismal prognosis. Off-label glofitamab may represent a critical res- cue strategy for patients lacking alternative options and may redefine therapeutic expectations in this otherwise un- met clinical setting."
IO biomarker • Aplastic Anemia • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • TP53
|
|
M. Schirru1; M. Bacciocchi1; A. Calvisi1; S. Chiriu1; A. Cucca1; L. Deiana1; M. P. Flagiello1; A. Galitzia2; L. Malloci1; M. Monne1; M. Murineddu1; A. Virdis1; R. Asproni1; A. Uras1; G. Piras1; A. Palmas1
|